DBV Technologies Completes Screening for VITESSE Phase 3 Clinical Trial
DBV Technologies has marked a major milestone by finishing the screening process for the VITESSE Phase 3 clinical trial. This trial is aimed at assessing the innovative Viaskin Peanut Patch, intended for children aged 4 to 7 years who suffer from peanut allergies.
Overview of the VITESSE Study
During the third quarter of this year, DBV successfully achieved its recruitment goals, and now the screening phase for the VITESSE study has come to a successful end. This critical clinical trial seeks to collect data regarding both the effectiveness and safety of the Viaskin Peanut Patch, which could represent a major advancement in treating peanut allergies among young children.
Why VITESSE is Significant
The VITESSE trial stands out as the largest immunotherapy clinical study dedicated to peanut allergies, showcasing DBV Technologies' dedication to improving treatments for these allergies. The company anticipates sharing topline results from the VITESSE clinical trial by the end of 2025.
The Significance of This Milestone
“Reaching this important milestone is truly exciting for us,” stated Dr. Pharis Mohideen, the Chief Medical Officer at DBV Technologies. He expressed appreciation for the many study centers that have shown commitment and dedication to this groundbreaking study. The support from participants and their families is invaluable, as it plays a crucial role in the development of new treatment options for food allergies.
Details About the Trial
The fully enrolled VITESSE study will run for 12 months and includes over 600 participants spread across 86 sites globally, with locations in North America, Europe, and Australia. This extensive outreach highlights DBV's commitment to inclusivity and expanding treatment options for the diverse communities affected by peanut allergies.
More About DBV Technologies
DBV Technologies is a biopharmaceutical company in the clinical stage, focusing on meeting significant unmet medical needs related to food allergies and other immunological conditions. Through its proprietary platform known as Viaskin, DBV aims to create innovative treatments that might reduce allergic reactions using a non-invasive technique called epicutaneous immunotherapy (EPIT™).
The Role of Technology and Its Impact
EPIT technology facilitates the introduction of minute quantities of biologically active compounds via the skin, with the goal of modifying the immune response and promoting desensitization to allergens. DBV is deeply committed to making a positive difference in the lives of individuals with food allergies. The company’s pipeline currently includes trials assessing the Viaskin Peanut Patch for toddlers and young children.
Global Operations and Presence
DBV Technologies is headquartered in Châtillon, France, and has operations in North America, with offices in Warren, NJ. The company's shares trade on Euronext Paris under the ticker symbol DBV, while its American Depositary Shares (ADSs) are available on the Nasdaq under the ticker DBVT.
Getting in Touch with DBV Technologies
If you're interested in learning more about DBV Technologies and its innovative treatment progress, the company invites you to visit their official website and connect with them on social media platforms.
Frequently Asked Questions
What is the VITESSE trial?
The VITESSE trial is a Phase 3 clinical study evaluating the Viaskin Peanut Patch in children aged 4 to 7 with peanut allergies.
What is the expected timeline for VITESSE results?
Topline results from the VITESSE trial are anticipated by the end of 2025.
What does Viaskin technology entail?
Viaskin is a proprietary technology developed by DBV that employs epicutaneous immunotherapy to deliver allergenic extracts through the skin.
How many participants are involved in the VITESSE trial?
The VITESSE trial involves over 600 participants across 86 international sites.
Where can I find more information about DBV Technologies?
More information is available on DBV Technologies' official website and its social media channels.
